在行情向好的背景下，与医药相关的主题基金产品也成为投资焦点。数据显示，自年初以来，包含医药 主题的基金产品收益亮眼。（数据来源：wind，统计区间：2025.1.1-2025.9.2。） 这其中，中银基金旗下的医药主题基金表现不俗，业绩在同类中排名较为靠前。据银河证券数据显示， 截至2025年8月末，中银创新医疗A过去一年、过去三年和过去五年同类排名均位于同类前五（4/85、 2/66、3/37）。另一只基金中银港股通医药A过去一年在同类中排名第一（1/42），该基金的特别之处 在于可投港股通比例较高，投资于港股通标的股票占非现金基金资产的比例不低于 80%。（中银创新 医疗同类排名为混合基金—行业偏股型基金—医药医疗健康行业偏股型基金（A类）；中银港股通医药 同类排名为混合基金-港股通偏股型基金-港股通偏股型基金（A类）；排名来源于银河证券，截至 2025.8.31。） 在政策与流动性双重加持下，A股近期放量上行，演绎结构性行情，各板块轮番走强。这其中，医药板 块今年以来表现持续活跃。Wind数据显示，截至2025年9月2日收盘，万得创新药指数年内涨幅已达 60.77%，大幅跑赢万得全A指数22.14%的涨 ...

Core Viewpoint - The A-share market is experiencing a recovery in sentiment, with nearly 20 equity funds resuming large-scale subscriptions, indicating a positive outlook for future macroeconomic conditions and corporate earnings improvement [1][4][5]. Group 1: Fund Subscription Resumption - Nearly 20 equity funds, including both active and passive types, have announced the resumption of large-scale subscriptions since the beginning of the year [1][3]. - Notable fund announcements include Huashang Fund resuming large subscriptions for its Huashang New Trend Preferred Fund, which has a scale of approximately 12.91 billion yuan and a stock position of about 91.54% as of Q3 2023 [2]. - Other funds, such as Invesco Great Wall and Guolian Fund, have also lifted restrictions on large subscriptions, reflecting a trend of easing limits to attract external capital [3][4]. Group 2: Fund Issuance Market Recovery - The fund issuance market is showing signs of recovery, with equity funds dominating the new offerings, contrasting with the previous year's focus on bond funds [4]. - In January 2024, 111 new funds were scheduled for issuance, with nearly 40% being equity funds, including 44 equity-mixed and ordinary stock funds [4]. - The previous year saw 377 bond funds issued, totaling approximately 819.86 billion yuan, which accounted for over 70% of the issuance [4]. Group 3: Market Sentiment Improvement - The A-share market has seen a general rise, with major indices like the ChiNext Index increasing by nearly 2% and the Shenzhen Component Index and Northbound 50 Index rising over 1% [5]. - Analysts believe that the current A-share market valuation is at a historical low, with expectations of macroeconomic recovery and improving corporate earnings contributing to a potential rebound in market sentiment [5][6]. - Morgan Stanley Fund highlights that the current market offers high value due to low valuations, particularly favoring low-volatility dividend and technology growth sectors [6][7].